肝康颗粒联合阿德福韦酯治疗肝炎肝硬化50例  

50 cases of treating hepatitis B cirrhosis with pellets of Gan Kang and adefovir dipivoxil

作　　者：郝明霞[1] 王新梅[1] 寇小妮[1] 

机构地区：[1]陕西中医学院附属医院感染病科,陕西咸阳712000

出　　处：《陕西能源职业技术学院学报》2010年第2期34-36,共3页

摘　　要：目的观察肝康颗粒联合阿德福韦酯治疗乙肝病毒引起肝炎肝硬化的临床疗效。方法选择100例乙型肝炎肝硬化患者随机分为治疗组和对照组，治疗组口服肝康颗粒联合阿德福韦酯，对照组单用阿德福韦酯，疗程均6个月，观察治疗前后患者的临床表现，肝脏功能，乙肝病毒基因定量（HBV—DNA），肝纤维化指标。结果治疗组在改善临床症状，恢复肝功能方面优于对照组（P〈0．05），HBV—DNA阴转无明显差异（P〉0．05），肝纤维化指标明显改善（P〈0．05）。结论肝康颗粒联合阿德福韦酯治疗乙型肝炎肝硬化能有效地改善临床症状，恢复肝功能，使患者HBV—DNA阴转，提高生存率。Objective： To observe the clinical effect of using pellets of Gan Kang and adefovir dipivoxil to treat hepatitis B cirrhosis. Methods： Choosing 100 cases of patients with hepatitis B cirrhosis, then divid them into two groups： treated group and control group. Treated group use pellets of Gan Kang and adefovir dipivoxil while the control group use adefovir dipivoxil （ ADV）, both course of treatment is six months. The patients clinical behaviour before and after treatment are observed, including quantitative hepatitis B virus （ HBV - DNA. Results： treated group are improving clinical symptoms and is superior to the control group （ P 〈 O. 05 ） in recovering liver function. HBV -DNA negative conversion has no significant differencs（ P 〉0.05） and liver fibrosis indexes has improved（P 〈 0.05 ）. Conclusion： Pellets of Gan Kang and adefovir dipivoxil treats hepatitis B cirrhosis obviously and make the patients HBV- DNA negative.

关 键 词：肝康颗粒 阿德福韦酯 乙型肝炎肝硬化 

分 类 号：S858.292[农业科学—临床兽医学]